Strides Pharma Scien

₹748.5 35.6 | 5%

WEBSITE BSE:532531 NSE : STAR 09 Dec, 12:47

Market Cap ₹6898 Cr.

Stock P/E -46.4

P/B 3

Current Price ₹748.5

Book Value ₹ 246.5

Face Value 10

52W High ₹1675.3

Dividend Yield 0.33%

52W Low ₹ 482.5

Edit Ratio

Strides Pharma Scien Research see more...

Overview Inc. Year: 1990Industry: Pharmaceuticals & Drugs

Strides Pharma Science Ltd is an totally India-based pharmaceutical corporation. The Company is targeted on development and manufacture of IP-led niche and pharmaceutical merchandise. It operates through segments: Bio-pharmaceutical and Pharmaceutical. Its geographical segment consists of Africa, Australia, Asia (aside from India), North America, Europe, India, and Others. The Company manufactures a number of niche and pharmaceutical products, which include a number of dosage forms inclusive of, liquids, lotions and ointments, soft gels, sachets, tablets, and modified release dosage codecs. It has eight manufacturing gadgets positioned in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the US (Florida) and Kenya (Nairobi). It is also engaged in production soft gelatin capsules. It develops and manufactures drugs within the anti-retro viral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious ailment drug segments for its institutional commercial enterprise.

Strides Pharma Scien Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Strides Pharma Scien Quarterly Results

#(Fig in Cr.)	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Net Sales	940	897	865	986	930	999	1038	1084	1088	1201
Other Income	14	23	26	27	9	36	9	-14	13	28
Total Income	954	921	891	1013	939	1035	1046	1070	1100	1230
Total Expenditure	880	799	749	831	763	846	844	854	871	965
Operating Profit	74	122	143	183	175	189	203	216	230	264
Interest	55	68	58	81	76	79	79	80	80	82
Depreciation	60	62	60	61	60	60	51	50	49	51
Exceptional Income / Expenses	-66	15	42	-7	-6	-165	-10	-8	-4	-4
Profit Before Tax	-107	7	65	34	33	-115	62	78	97	128
Provision for Tax	-28	-38	4	7	10	-7	10	19	17	21
Profit After Tax	-79	45	61	27	24	-107	52	59	80	106
Adjustments	-57	-22	-141	-36	-31	-24	-2	-41	-10	-13
Profit After Adjustments	-136	23	-80	-10	-7	-131	50	18	70	93
Adjusted Earnings Per Share	-15.1	2.5	-8.9	-1.1	-0.8	-14.5	5.4	2	7.6	10.1

Strides Pharma Scien Profit & Loss

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Net Sales	1341	1196	2862	2755	2845	2178	2752	3316	3070	3688	4051	4411
Other Income	60	39	92	161	88	41	53	59	133	135	50	36
Total Income	1401	1234	2954	2917	2933	2219	2805	3375	3204	3824	4101	4446
Total Expenditure	1118	967	2448	2228	2443	1936	2236	2689	3092	3303	3318	3534
Operating Profit	284	267	506	688	491	283	569	686	112	521	783	913
Interest	109	47	168	183	196	79	156	150	177	261	314	321
Depreciation	56	64	131	126	154	117	174	206	233	243	221	201
Exceptional Income / Expenses	-27	-7	-41	-36	-44	22	-78	43	-244	-17	-189	-26
Profit Before Tax	92	149	161	343	80	62	55	275	-653	-286	-117	365
Provision for Tax	325	148	42	63	6	-27	11	32	-178	-55	32	67
Profit After Tax	-233	1	118	280	74	89	43	244	-474	-231	-149	297
Adjustments	2000	844	-10	120	590	235	-7	25	14	28	78	-66
Profit After Adjustments	1767	845	109	400	665	325	36	268	-460	-203	-71	231
Adjusted Earnings Per Share	296.6	141.7	12.1	44.7	74.2	36.3	4.1	29.9	-51.3	-22.4	-7.7	25.1

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	10%	7%	13%	12%
Operating Profit CAGR	50%	5%	23%	11%
PAT CAGR	0%	NAN%	NAN%	0%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	39%	17%	15%	-2%
ROE Average	-7%	-12%	-5%	-2%
ROCE Average	4%	-2%	1%	5%

Strides Pharma Scien Balance Sheet

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Shareholder's Funds	1007	1145	2658	2749	2464	2649	2527	2777	2359	2212	2126
Minority's Interest	76	19	50	134	155	153	67	37	24	-39	-54
Borrowings	276	267	2627	1638	1551	1807	604	883	836	1140	671
Other Non-Current Liabilities	31	18	133	411	516	536	210	382	130	71	-50
Total Current Liabilities	707	1020	1892	3104	1896	2662	2545	2738	3412	2990	2879
Total Liabilities	2096	2469	7360	8035	6585	7807	5953	6817	6761	6373	5572
Fixed Assets	555	701	2679	2909	2903	3570	2026	2151	2333	2298	1853
Other Non-Current Assets	233	339	1167	1334	1198	1188	1555	1848	1065	832	750
Total Current Assets	1309	1429	3515	3792	2447	3049	2371	2817	3362	3135	2969
Total Assets	2096	2469	7360	8035	6585	7807	5953	6817	6761	6373	5572

Strides Pharma Scien Cash Flow

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Opening Cash & Cash Equivalents	132	586	299	1111	515	256	366	182	126	171	304
Cash Flow from Operating Activities	-272	83	73	288	187	60	205	481	-258	44	701
Cash Flow from Investing Activities	4077	52	-2225	-687	583	-148	1306	-521	-119	302	-150
Cash Flow from Financing Activities	-3319	-421	2944	338	-1016	194	-1709	-16	421	-214	-693
Net Cash Inflow / Outflow	487	-286	792	-60	-246	106	-199	-55	45	133	-143
Closing Cash & Cash Equivalent	586	298	1111	515	256	366	182	126	171	304	161

Strides Pharma Scien Ratios

#	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Earnings Per Share (Rs)	296.6	141.74	12.15	44.7	74.25	36.25	4.06	29.93	-51.25	-22.44	-7.68
CEPS(Rs)	-29.6	10.91	27.91	45.39	25.51	23.08	24.23	50.19	-26.87	1.37	7.85
DPS(Rs)	505	108	4	4.5	2	3	14	2.5	0	1.5	2.5
Book NAV/Share(Rs)	168.99	191.91	296.83	306.41	274.26	294.94	281.55	309.09	262.48	242.83	230.95
Core EBITDA Margin(%)	16.59	19.08	14.46	19.14	14.14	7.26	10.95	11.45	-0.4	6.17	11.73
EBIT Margin(%)	14.9	16.34	11.49	19.1	9.71	4.25	4.47	7.77	-8.93	-0.4	3.16
Pre Tax Margin(%)	6.81	12.39	5.61	12.45	2.81	1.87	1.16	5.03	-12.25	-4.58	-1.87
PAT Margin (%)	-17.28	0.08	4.13	10.15	2.61	2.67	0.92	4.45	-8.9	-3.7	-2.38
Cash Profit Margin (%)	-13.09	5.42	8.71	14.73	8.02	6.19	4.61	8.22	-4.53	0.2	1.15
ROA(%)	-6.76	0.04	2.4	3.63	1.02	1.24	0.63	3.82	-6.99	-3.52	-2.49
ROE(%)	-15.37	0.09	6.22	10.37	2.86	3.5	1.68	9.21	-18.49	-10.15	-6.88
ROCE(%)	7.76	10.92	7.98	8.32	4.83	2.61	4.06	9.08	-9.49	-0.49	4.15
Receivable days	114.8	114.71	90.73	134.38	120.47	102.23	74.33	68.09	79.41	73.25	71.28
Inventory Days	83.78	58.37	52.34	89.14	82.42	78	64.17	66.13	81.35	67.8	66.36
Payable days	166.25	127.59	118.97	220.72	196.71	269.25	274.24	264.54	267.95	230.4	204.02
PER(x)	1.31	8.31	89.61	24.54	9.05	13.01	79.39	28.21	0	0	0
Price/Book(x)	2.29	6.14	3.67	3.58	2.45	1.6	1.15	2.73	1.32	1.18	3.39
Dividend Yield(%)	130.41	9.16	0.37	0.41	0.3	0.64	4.34	0.3	0	0.52	0.32
EV/Net Sales(x)	1.96	6.5	4.53	4.78	2.89	3.18	1.68	2.86	1.86	1.37	2.32
EV/Core EBITDA(x)	9.24	29.06	25.6	19.14	16.78	24.46	8.11	13.84	51.09	9.69	12.03
Net Sales Growth(%)	39.43	-10.82	139.34	-3.73	3.25	-23.43	26.33	20.49	-7.41	20.13	9.83
EBIT Growth(%)	-75.05	-2.3	67.73	60.06	-47.51	-48.7	48.5	102.24	-211.81	94.73	888.18
PAT Growth(%)	-132.63	100.42	0	136.75	-73.45	20.19	-51.42	462.28	-294.53	51.31	35.67
EPS Growth(%)	106.11	-52.21	-91.43	268.03	66.09	-51.18	-88.79	636.7	-271.23	56.22	65.76
Debt/Equity(x)	0.54	0.78	1.34	1.35	1.03	1.22	0.78	0.76	1.18	1.27	1.14
Current Ratio(x)	1.85	1.4	1.86	1.22	1.29	1.15	0.93	1.03	0.99	1.05	1.03
Quick Ratio(x)	1.6	1.2	1.54	0.99	1	0.82	0.62	0.59	0.64	0.67	0.64
Interest Cover(x)	1.84	4.13	1.95	2.87	1.41	1.79	1.35	2.84	-2.69	-0.1	0.63
Total Debt/Mcap(x)	0.24	0.13	0.36	0.38	0.42	0.76	0.68	0.28	0.9	1.07	0.34

Strides Pharma Scien Shareholding Pattern

#	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoter	30.37	31.07	30.89	28.27	28.07	27.78	27.39	25.88	25.86	25.84
FII	21.21	21.38	18.93	18.8	16.67	17.2	19.45	24.57	26.71	30.08
DII	16.62	15.52	18.89	18.34	20.05	19.95	19.41	18.05	18.56	18.25
Public	31.79	32.03	31.28	34.59	35.21	35.06	33.75	31.5	28.87	25.83
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoter	2.73	2.81	2.79	2.55	2.54	2.51	2.52	2.38	2.38	2.38
FII	1.9	1.93	1.71	1.7	1.51	1.55	1.79	2.26	2.45	2.77
DII	1.49	1.4	1.71	1.66	1.81	1.8	1.78	1.66	1.71	1.68
Public	2.86	2.89	2.82	3.12	3.18	3.17	3.1	2.9	2.65	2.38
Others	0	0	0	0	0	0	0	0	0	0
Total	8.98	9.03	9.03	9.03	9.03	9.03	9.19	9.19	9.19	9.2

Pros

Debtor days have improved from 230.4 to 204.02days.
Company has reduced debt.

Cons

Promoter holding is low: 25.84%.
Company has a low return on equity of -12% over the last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Strides Pharma Scien News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Strides Pharma Scien

Add Watchlist

Strides Pharma Scien Research see more...

Overview Inc. Year: 1990Industry: Pharmaceuticals & Drugs

Strides Pharma Scien Share Price

Alert Data

Quarterly Price

Peer Comparison

Strides Pharma Scien Quarterly Results

Strides Pharma Scien Profit & Loss

Growth Rates

Strides Pharma Scien Balance Sheet

Strides Pharma Scien Cash Flow

Strides Pharma Scien Ratios

Strides Pharma Scien Shareholding Pattern

Strides Pharma Scien News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!